{"filings":[{"id":1083798,"accession_number":"0001104659-26-074577","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2026-06-16T20:06:02+00:00","items":[],"status":"ready","headline":"Century Therapeutics CSO Chad Cowan moves to part-time with reduced salary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chad Cowan continues as CSO on part-time basis; salary cut to $296,150 annually.","Eligible for pro-rated annual performance-based target bonus.","Upon company termination or resignation, entitled only to accrued unpaid base salary.","A&R Employment Agreement to be filed as exhibit to Q2 2026 10-Q.","Agreement effective June 15, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1027325,"accession_number":"0001104659-26-073429","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2026-06-12T20:06:04+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Century Therapeutics shareholders approve increase in authorized common stock to 450M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to increase authorized common stock from 300M to 450M shares; effective June 12, 2026.","Alessandro Riva, M.D. and Han Lee, Ph.D., M.B.A. elected as Class II directors until 2029 annual meeting.","Ratification of Ernst & Young LLP as independent auditor for fiscal 2026 received 135.6M votes for, 107K against.","Proposal to adjourn meeting passed but was unnecessary after share amendment approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":918317,"accession_number":"0001104659-26-071383","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2026-06-08T20:10:52+00:00","items":["8.01","9.01"],"status":"ready","headline":"Century Therapeutics presents preclinical data for CNTY-813; glucose control >8 months, IND on track for Q4 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CNTY-813 maintained glucose control for >8 months in diabetic mouse models without immunosuppression.","No tumorigenesis observed in >140 mice with >1 billion cells infused over 3 months follow-up.","Allo-Evasion 5.0 edits provided protection from NK cells, antibody-mediated phagocytosis, and maintained insulin secretion in humanized mouse model.","Phase 1 manufacturing process established; consistent product quality across 11 samples from GMP Master Cell Bank.","IND submission on track for Q4 2026; initial clinical data expected in 2H 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50441,"accession_number":"0001104659-26-059824","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2026-05-13T12:09:13+00:00","items":["2.02","9.01"],"status":"ready","headline":"Century Therapeutics reports Q1 net loss of $21.6M; cash runway into Q1 2029; CNTY-813 IND on track for 4Q 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.6M for Q1 2026 vs net income of $76.6M in Q1 2025; R&D $17.1M, G&A $6.6M.","Cash, cash equivalents and marketable securities $217.0M as of March 31, 2026; runway into Q1 2029.","CNTY-813 (type 1 diabetes iPSC islet) IND submission on track for 4Q 2026; initial clinical data expected 2H 2027; ADA presentation June 8, 2026.","CNTY-308 (CD19 CAR-iT) to enter clinic in 2026 pending regulatory clearance; targeting B-cell mediated diseases.","Completed $135M oversubscribed private placement in January 2026; net cash used in ops $25.3M (down from $34.6M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109917,"accession_number":"0001104659-26-035256","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Century Therapeutics updates ATM program; $131.6M remaining under $150M facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New prospectus supplement filed March 26, 2026 for existing ATM program under effective shelf.","Up to $150M in common stock may be sold via ATM; $18.38M already sold.","$131.62M remains available for future issuance through TD Securities as agent.","Goodwin Procter LLP opinion on share validity included as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109916,"accession_number":"0001104659-26-026761","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Century Therapeutics FY2025 net loss $9.6M; $135M placement extends cash into Q1 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.6M improved from $126.6M in 2024; collaboration revenue from BMS rose to $109.2M (from $6.6M).","Cash, cash equivalents, and securities $117.1M at Dec 31, 2025; with $135M Jan 2026 placement, runway extended to Q1 2029.","CNTY-813 (T1D beta islet therapy) IND submission expected Q4 2026; initial clinical data anticipated 2H 2027.","CNTY-308 (CD19-targeted CAR-iT) on track for clinical entry in 2026; CARAMEL IST data expected later this year.","Strengthened balance sheet via oversubscribed $135M private placement led by TCGX; new board members appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109915,"accession_number":"0001104659-26-006236","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Century Therapeutics regains Nasdaq bid price compliance; reverse split not needed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Century on Jan 22, 2026 that it regained compliance with minimum $1.00 bid price rule.","Stockholders approved reverse stock split (1:5–1:30) at special meeting earlier that day.","Company will not implement the reverse split due to regained compliance.","No other business was conducted; adjournment proposal was unnecessary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109914,"accession_number":"0001104659-26-002748","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Century Therapeutics updates investor presentation focused on T1D pipeline; no specific new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed updated slide presentation under Item 7.01 used in investor meetings, dated January 12, 2026.","Presentation titled 'Unlocking the Value of our Pipeline for T1D' signals strategic focus on type 1 diabetes.","Available text contains only cover slide and forward-looking statements; no new clinical or financial details visible.","No changes to guidance, pipeline milestones, or financial outlook were provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109913,"accession_number":"0001104659-26-001952","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Century Therapeutics raises $135M in oversubscribed private placement to fund CNTY-813 T1D program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$135M; 117.4M shares/pre-funded warrants + 58.7M warrants at $1.15 per unit.","Led by new investor TCGX; includes RA Capital, Commodore, Deep Track, RTW, Venrock, T1D Fund.","Proceeds fund lead candidate CNTY-813 (beta islet cell for T1D); cash runway extended to Q1 2029.","IND submission for CNTY-813 expected in 2026; initial clinical data anticipated in 2027.","Full exercise of warrants could yield additional ~$153M at $2.60 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126499,"accession_number":"0001104659-25-124836","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Carlo Rizzuto resigns from Century Therapeutics board effective Dec 18, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carlo Rizzuto, Ph.D. resigned from the board of directors effective December 18, 2025.","Resignation was not due to any disagreement with the Company on operations, policies, or practices.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126498,"accession_number":"0001104659-25-120654","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Century Therapeutics furnishes updated investor presentation on Dec 12, 2025","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated slide presentation attached as Exhibit 99.1, dated December 2025.","Presentation titled 'Advancing Pipeline of Transformative Cell Therapies' provided to investors.","No specific financial or pipeline updates disclosed in the filing excerpt; full deck not provided.","Information furnished under Item 7.01 and not deemed filed for SEC purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126497,"accession_number":"0001104659-25-119494","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Century Therapeutics appoints Dr. Murphy and Dr. Lee to Board, expanding from six to eight members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from six to eight directors; Dr. Murphy (Class III, term to 2027) and Dr. Lee (Class II, term to 2026) appointed.","Dr. Murphy brings life science investment experience; Dr. Lee brings corporate development and CFO background from biotech firms.","Each new director received an initial option grant of 88,000 shares vesting over 36 months and a $40,000 annual cash retainer.","Dr. Murphy joins Compensation and Nominating/Governance Committees; Dr. Lee joins Audit and Compensation Committees.","Appointments effective December 9, 2025; both deemed independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126496,"accession_number":"0001104659-25-110862","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Century Therapeutics announces CNTY-813 T1D program; Q3 net loss $34.4M, cash $132.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CNTY-813 is iPSC-derived beta islet therapy for T1D; preclinical data show reversal of diabetes in mouse models.","IND-enabling studies for CNTY-813 to start by year-end 2025; IND submission planned as early as 2026.","Q3 2025 net loss $34.4M vs $31.2M in Q3 2024; R&D expenses down to $22.5M from $27.2M.","Cash and investments $132.7M as of Sep 30, 2025; estimated cash runway into Q4 2027.","Discontinuing company-sponsored CALiPSO-1 trial; continuing CARAMEL IST with data expected Dec 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143241,"accession_number":"0001104659-25-085658","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Century Therapeutics gets Nasdaq extension to Feb 2026 for bid price compliance; transfers to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received 180-day extension until Feb 23, 2026 to meet $1.00 minimum bid price rule after Aug 26 initial deadline.","Nasdaq approved transfer from Global Select to Capital Market effective Aug 27, 2025; stock continues under IPSC.","Company will consider a reverse stock split to cure the bid price deficiency.","No assurance of regaining compliance; delisting remains possible if price fails to close at $1.00 for 10 consecutive days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143240,"accession_number":"0001104659-25-078617","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Century Therapeutics Q2 net loss $32.5M; cash runway into Q4 2027; CEO named Board Chair","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $32.5M for Q2 2025 (vs. $31.2M in Q2 2024); cash & equivalents $158.5M as of June 30.","Cash runway extended into Q4 2027 after workforce reduction completed July 2025.","CEO Brent Pfeiffenberger appointed Board Chair; Joseph Jimenez steps down, becomes special advisor.","CNTY-101 CALiPSO-1 trial dosing two patients; clinical data expected by year-end 2025.","CNTY-308 enters IND-enabling studies; clinical start planned in 2026."],"consensus_eps_estimate":-0.3835,"consensus_eps_actual":0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":109164000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143239,"accession_number":"0001104659-25-066091","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["2.05","5.02"],"status":"ready","headline":"Century Therapeutics cuts 51% of workforce; CFO and CDO to depart","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved reduction in force of ~51% of employees; expects $3.7M in severance costs.","CFO Morgan Conn to depart effective July 11; SVP Finance Douglas Carr named interim principal financial officer.","Chief Development Officer Adrienne Farid to depart effective July 31.","Workforce reduction substantially complete by end of Q3 2025; company focusing on highest-potential programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161372,"accession_number":"0001104659-25-059950","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Century Therapeutics stockholders elect two Class I directors and ratify E&Y as auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Daphne Quimi elected with 52,593,454 votes for; Carlo Rizzuto elected with 51,373,990 votes for.","Ratification of Ernst & Young LLP as independent auditor for 2025 passed with 71,768,193 votes for.","Broker non-votes of 15,072,004 on director elections; no broker non-votes on auditor ratification.","Annual meeting held virtually on June 12, 2025; record date April 16, 2025 with 86,158,758 shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161371,"accession_number":"0001104659-25-049454","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Century Therapeutics Q1 net income $76.6M on BMS termination revenue; CNTY-101 dosing started","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $76.6M vs $28.1M loss in Q1 2024, driven by $109.2M collaboration revenue from BMS deal termination.","Cash, equivalents, and securities $185.8M as of March 31, 2025, down from $220.1M; estimated runway into Q4 2026.","First patient dosed in Phase 1 CALiPSO-1 trial of CNTY-101 for autoimmune disease; clinical data expected by end of 2025.","CNTY-308 (CD19-targeted CAR-iT) on track to enter IND-enabling studies mid-2025.","R&D expenses increased to $26.6M from $23.4M due to clinical trial costs and preclinical program advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":109164000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179535,"accession_number":"0001104659-25-025559","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Century Therapeutics FY2024 net loss $126.6M; discontinues ELiPSE-1, focuses on CNTY-308","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $126.6M for FY2024 ($136.7M in 2023); cash $220.1M, runway into Q4 2026.","Discontinued ELiPSE-1 Phase 1 trial for CNTY-101 in R/R NHL; data not transformational.","Pipeline re-prioritized to four programs led by CNTY-308 (CD19 CAR-iT); IND-enabling studies mid-2025.","First patient dosed in CALiPSO-1 Phase 1 trial for CNTY-101 in autoimmunity; CARAMEL IIT to start mid-2025.","Collaboration revenue from BMS $6.6M; R&D expenses $107.2M (up from $92.7M) driven by trial and manufacturing costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179534,"accession_number":"0001104659-25-019145","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Century Therapeutics receives Nasdaq bid price deficiency notice; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Century Therapeutics on Feb 26, 2025 that its stock closed below $1.00 for 31 consecutive business days.","Company has until August 25, 2025 to regain compliance by maintaining bid price of at least $1.00 for 10 consecutive days.","If not compliant, Century may transfer to Nasdaq Capital Market for an additional 180-day cure period.","Company plans to monitor bid price and consider options; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179533,"accession_number":"0001104659-25-002841","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Century Therapeutics reports preliminary Q4 2024 cash of ~$220M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Dec 31, 2024, cash, cash equivalents and investments approx $220M.","Preliminary, unaudited; subject to change upon completion of year-end closing procedures.","Full year 2024 financial results to be included in upcoming Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196257,"accession_number":"0001104659-24-128491","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"BMS terminates collaboration with Century Therapeutics without cause; effective March 12, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BMS notified Century on Dec 12, 2024 of termination of the 2022 Research, Collaboration and License Agreement.","Termination covers all iPSC-derived NK and gamma delta T cell programs for hematologic malignancies.","Century will evaluate opportunities in AML and multiple myeloma under ongoing strategic review of pre-clinical pipeline.","Both parties will cooperate on termination provisions; no financial details of termination disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196256,"accession_number":"0001104659-24-114136","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Century Therapeutics Q3 net loss $31.2M; cash $244.7M, expands CNTY-101 autoimmune trial, 83% ORR in lymphoma","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $31.2M in Q3 2024; cash $244.7M; expects cash to support operations into H2 2026.","Expanded CNTY-101 autoimmune trial to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy; basket protocol.","ELiPSE-1 interim: 83% ORR, 33% CRR at DL3B; no DLTs or high-grade CRS/ICANS; DL4B dosing initiated.","Strategic pipeline review to conclude Q1 2025; organizational restructuring extended cash runway.","Appointed Morgan Conn CFO and Chad Cowan CSO; Hy Levitsky transitioned to advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":2416000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212543,"accession_number":"0001104659-24-102988","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Century Therapeutics appoints Morgan Conn, Ph.D. as CFO effective Oct 14, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Morgan Conn, formerly CBO of Pharvaris, appointed CFO; effective October 14, 2024.","Annual base salary of $470,000; target bonus of 40% of base; $100,000 signing bonus.","Equity award: option to purchase 360,890 shares and RSU covering 60,148 shares.","Option vests 25% on first anniversary, remainder monthly over 3 years; RSU vests 25% first year, quarterly thereafter.","Severance includes 9 months salary and COBRA, extended to 12 months upon change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212542,"accession_number":"0001104659-24-087013","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Century Therapeutics Q2 2024: Cash $269.6M, initiates Phase 1 SLE trial, advances CNTY-101","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Initiated Phase 1 CALiPSO-1 trial of CNTY-101 in Systemic Lupus Erythematosus, with protocol amended to include Lupus Nephritis cohort; expects initial data by year-end 2024.","Presented interim ELiPSE-1 trial data at ASCO showing encouraging efficacy and tolerability in relapsed/refractory B-cell lymphomas; dose escalation completed, dose expansion expected in 2H 2024.","Ended Q2 2024 with $269.6 million cash, equivalents, and investments; cash runway into 2026. GAAP operating expense guidance $150-$160 million.","Completed $60 million private placement and acquired Clade Therapeutics in April 2024, enhancing Allo-Evasion platform and adding preclinical αβ iT programs.","R&D expenses $27.2 million for Q2 2024 vs $22.7 million prior year; net loss $31.2 million vs $33.3 million."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":1625000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212541,"accession_number":"0001104659-24-078322","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Century Therapeutics updates pipeline; CNTY-101 achieves 40% CRR at higher doses; SLE trial starts Q3 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CNTY-101 ELiPSE-1 Phase 1 data: 30% CRR, 40% ORR overall; 40% CRR, 60% ORR at highest dose levels in Schedule A.","CNTY-101 shows favorable safety: no GvHD, low-grade CRS/ICANS, manageable outpatient administration.","Phase 1 CALiPSO-1 trial for SLE (systemic lupus erythematosus) initiated early Q3 2024; initial data expected by YE 2024.","Cash of $249.9M at 1Q24 end provides runway into 2026.","Pursuing additional autoimmune regulatory submissions for CNTY-101 in 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231531,"accession_number":"0001104659-24-075201","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K/A","filed_at":"2024-06-26T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Century Therapeutics files financials of acquired Clade; Clade had $38.6M net loss in 2023","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Clade's audited FY2023 net loss $38.6M, accumulated deficit $51.8M as of Dec 31, 2023.","Clade had $14.2M cash at year-end 2023; going concern doubt noted for next 12 months.","Unaudited pro forma combined financials for FY2023 filed; acquisition closed April 11, 2024.","No deal value disclosed in this amendment; prior 8-K on April 11 announced acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231537,"accession_number":"0001104659-24-074339","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Century Therapeutics shareholders elect three Class III directors, ratify auditor, approve charter amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Kimberly Blackwell, Joseph Jimenez, Brent Pfeiffenberger elected as Class III directors with >59M votes for each.","Ratification of Ernst & Young as independent auditor for FY2024: 72.3M for, 1.1M against, 24k abstentions.","Amendment to limit officer liability approved: 64.4M for, 1.5M against, 38k abstentions (7.4M broker non-votes).","All proposals passed with substantial majorities; no contested items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231536,"accession_number":"0001104659-24-067446","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Century Therapeutics reports Phase 1 ELiPSE-1 data: 30% CRR, 40% ORR in R/R NHL; no DLTs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of March 27, 2024, 12 patients evaluable for safety; no DLTs or GvHD observed; most cycles outpatient.","Across all dose levels (10 evaluable), 30% complete response rate and 40% objective response rate.","At Schedule A dose levels 300M and 1B cells, 40% CRR and 60% ORR in 5 heavily pre-treated patients.","Novel cfDNA assay suggests CNTY-101 persists in tissues; AUC trends with dose.","Dose escalation continues at DL3B (3 weekly infusions of 1B cells) and DL4A (single 3B cells)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231535,"accession_number":"0001104659-24-059124","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Century Therapeutics Q1 2024 net loss $28.1M; expands autoimmune plans","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $28.1M for Q1 2024 vs $31.3M in Q1 2023; R&D expenses $23.4M, down from $24.9M.","Cash, cash equivalents and marketable securities $249.9M as of March 31, 2024; cash runway into 2026.","Closed $60M private placement led by Bain Capital Life Sciences in April 2024.","Plans additional regulatory filings for CNTY-101 in autoimmune diseases beyond SLE in H2 2024.","FY2024 GAAP operating expense guidance raised to $150-160M (prior $135-145M) due to Clade acquisition and expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":855000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231534,"accession_number":"0001104659-24-046373","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["1.01","2.01","3.02","7.01","9.01"],"status":"ready","headline":"Century Therapeutics raises $60M and acquires Clade Therapeutics to expand autoimmune pipeline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Private placement of ~15.87M shares at $3.78 (April 10 close) led by Bain Capital Life Sciences; expected close April 15, 2024.","Acquisition of Clade Therapeutics for ~$35M upfront ($15M cash + 4.535M shares) plus up to $10M milestone payment.","Expanding CNTY-101 into additional autoimmune indications beyond SLE; CALiPSO-1 trial on track for H1 2024 initiation.","Cash runway extended into 2026 with net proceeds from placement; pipeline adds three preclinical programs from Clade's ab iT platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231533,"accession_number":"0001104659-24-046247","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Century Therapeutics updates pipeline; CNTY-101 shows durable responses, no allo-rejection in Ph1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CNTY-101 (CD19 iNK) in Ph1 ELiPSE-1 shows favorable safety, 2 CRs including 6-month durable CR, no allo-rejection.","Plan to initiate Ph1 CALiPSO-1 trial in SLE in H1 2024; initial data expected by YE 2024.","Cash, cash equivalents, and investments of $261.8M at end of Q4 2023; runway into 2026.","Platform includes Allo-Evasion edits enabling repeat dosing without lymphodepletion; advancing iNK and γδ iT cell programs.","Additional ELiPSE-1 data expected mid-2024; pursuing additional autoimmune health authority filings in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231532,"accession_number":"0001104659-24-044909","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Century Therapeutics presents novel iPSC-derived cell therapy preclinical data at AACR 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CD19xCD22 bispecific CAR showed cytotoxicity against CD19/CD22 tumor cells in vitro and in xenograft models.","Allo-Evasion platform: combining HLA-E and HLA-G offered best protection against NK-mediated rejection of iPSC-derived cells.","NECTIN4-targeted iPSC-derived CAR-T demonstrated tumor inhibition comparable to Enfortumab-based CAR in OVCar-3 xenografts.","CXCR4 transgene in iPSC-derived NK cells enhanced migration and anti-tumor efficacy in vivo, eliminating bone disease.","Novel inhibitory CAR targeting DSG1 designed to reduce off-tumor skin toxicity of NECTIN4 therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249887,"accession_number":"0001104659-24-034239","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Century Therapeutics reports FY2023 net loss $136.7M; cash $261.8M, runway into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $136.7M in 2023 vs $131.0M in 2022; R&D expenses $92.7M, down from $97.2M.","Cash, cash equivalents and investments $261.8M as of Dec 31, 2023; net cash used in ops $88.3M.","Collaboration revenue from BMS agreement $2.2M in 2023, down from $5.2M in 2022.","One-time impairment charge of $16.4M from consolidating facilities in Philadelphia and Seattle.","FY2024 GAAP operating expense guidance $135M-$145M; cash runway expected into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249886,"accession_number":"0001104659-24-005271","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Century Therapeutics CFO Michael Diem resigns; Douglas Carr named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Michael C. Diem resigned effective Feb 2, 2024; company has initiated a search for a permanent replacement.","Douglas Carr, SVP Finance and Operations, will serve as interim principal financial officer following Dr. Diem's departure.","Dr. Diem's resignation is not due to any disagreement with the company's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267369,"accession_number":"0001104659-23-124911","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Century Therapeutics presents initial CNTY-101 data supporting multi-dosing strategy at ASH","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single-patient case study at Dose Level 1 (100 million cells) showed six-month durable complete response in high-risk R/R B-cell lymphoma","CNTY-101 was generally well tolerated with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity observed","Pharmacokinetic data suggested CNTY-101 exposure maintained upon additional cycles without lymphodepletion due to lack of allo-rejection","Company to host conference call Dec 11 to review additional clinical results from Dose Levels 1 and 2 and plans for systemic lupus erythematosus"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267368,"accession_number":"0001104659-23-123816","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA clears IND for Century's CNTY-101 in systemic lupus erythematosus","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA notified Century that Phase 1 trial of CNTY-101 may proceed in moderate-to-severe SLE patients who failed ≥2 immunosuppressive therapies.","This is the second IND clearance for CNTY-101 and first in autoimmune/inflammatory disease; previous IND for B-cell malignancies.","Trial expected to start H1 2024 with initial data by year-end 2024; evaluates safety, tolerability, PK, clinical response.","CNTY-101 is an allogeneic iPSC-derived NK cell with 6 genetic edits including CD19 CAR, Allo-Evasion, IL-15, and safety switch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267367,"accession_number":"0001104659-23-117704","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Century Therapeutics appoints Brent Pfeiffenberger as President and CEO, effective Dec 4, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brent Pfeiffenberger appointed CEO and to Board; Gregory Russotti transitions to Chief Technology and Manufacturing Officer.","Pfeiffenberger receives $625K base salary, 55% target bonus, $200K signing bonus, $450K retention bonus, and equity awards.","Equity includes options for 573,691 shares and RSUs covering 1,173,775 shares (Initial RSU) plus $450K value Second RSU.","Russotti's new role carries $525K base salary and 45% annual target bonus; prior interim CEO role ends Dec 4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267366,"accession_number":"0001104659-23-116008","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Century Therapeutics Q3 net loss $32.7M, appoints Brent Pfeiffenberger CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Brent Pfeiffenberger appointed CEO effective Dec 4, 2023; Greg Russotti becomes Chief Technology and Manufacturing Officer.","Cash and investments $284.3M as of Sep 30, 2023; cash runway into 2026.","Q3 2023 net loss $32.7M vs $30.7M in Q3 2022; R&D expenses down to $22.8M from $25.9M.","Expanded license with FUJIFILM Cellular Dynamics for iPSC-derived cell therapies in autoimmune/inflammatory diseases.","Initial Phase 1 ELiPSE-1 data for CNTY-101 in B-cell lymphomas to be presented at ASH Dec 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":1967000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267365,"accession_number":"0001104659-23-106149","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2023-10-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Century Therapeutics updates investor deck highlighting pipeline, Allo-Evasion 3.0, and cash runway into 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and investments of $301M at Q2 2023; runway extends into 2026.","ELiPSE-1 trial for CNTY-101 (iNK CD19) ongoing; initial data expected by end of 2023, PoC in 2024.","Pipeline includes CNTY-102 (iT CD19/CD22 dual-target) and CNTY-107 (iT Nectin-4); BMS collaboration for CNTY-104 (AML) and CNTY-106 (myeloma).","Allo-Evasion 3.0 incorporates 4 edits (β2M KO, CIITA KO, HLA-E KI, HLA-G KI) to protect against NK cell killing.","CNTY-101 designed with Allo-Evasion to enable repeat dosing without additional lymphodepletion; first CD19 agent with this approach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284620,"accession_number":"0001104659-23-089091","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Century Therapeutics Q2 net loss $33.3M; cash $301M; CNTY-101 data expected by year end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $33.3M for Q2 2023 vs $31.0M in Q2 2022; net cash used in operations $48.5M in H1 2023.","Cash, equivalents, and investments $301.0M as of June 30, 2023; runway expected into 2026.","Phase 1 ELiPSE-1 trial of CNTY-101 ongoing; initial data from Schedule A expected by year end 2023.","Full year GAAP operating expense guidance $135M-$145M; includes $12M-$17M stock-based compensation.","Recorded $4.2M impairment charge for consolidation of two leased facilities in Philadelphia."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":1819000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304344,"accession_number":"0001104659-23-076308","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Century Therapeutics elects three Class II directors and ratifies Ernst & Young at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Class II directors: Cynthia Butitta, Timothy Walbert, Alessandro Riva; each term until 2026.","Butitta: 50.6M for, 0.8M withheld; Walbert: 47.6M for, 3.9M withheld; Riva: 50.7M for, 0.8M withheld.","Broker non-votes on director election: 3,952,285.","Ratified Ernst & Young as independent auditor for 2023: 55.4M for, 5K against, 2.8K abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304343,"accession_number":"0001104659-23-058762","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Century Therapeutics Q1 net loss $31.3M; cash $334.8M; CNTY-101 data expected by year end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $31.3M vs $37.5M prior year; R&D expenses $24.9M, G&A $8.9M.","Cash, equivalents, investments $334.8M as of March 31, 2023; cash runway into 2026.","CNTY-101 Phase 1 ELiPSE-1 trial ongoing; initial data from Schedule A expected by year end 2023.","FY2023 GAAP operating expense guidance $135-145M; non-cash stock comp $12-17M.","Leadership: Greg Russotti interim CEO (since March), Michael Diem CFO, Hy Levitsky President of R&D."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":1720000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304342,"accession_number":"0001104659-23-056599","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Century Therapeutics repays $10.6M Hercules loan, terminates Loan Agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Prepaid $10.6M aggregate payoff including $100K prepayment charge and $395K exit fee.","Original $30M term loan facility; only $10M drawn with variable rate (greater of prime+6.30% or 9.55%).","All obligations under September 2020 Loan Agreement satisfied and terminated as of May 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304340,"accession_number":"0001104659-23-056605","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K/A","filed_at":"2023-05-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Century Therapeutics details CEO Flores' severance and CFO Diem's compensation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Flores receives 12 months base salary severance, COBRA reimbursement, and extended option exercise to 3 years.","80,100 unvested shares of restricted stock fully vest after 6-month advisory period.","CFO Diem's base salary increased to $500,000 with 45% bonus target.","Diem receives $500,000 RSU grant vesting 50% Nov 2023 and rest by Nov 2024 or performance milestone.","Separation agreement includes non-disparagement and cooperation clauses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304341,"accession_number":"0001104659-23-046197","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Century Therapeutics CEO Osvaldo Flores steps down; Gregory Russotti named interim CEO, Michael Diem appointed CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Osvaldo Flores stepped down as President, CEO, and Board member effective April 11, 2023; no disagreement with the company.","Board appointed Gregory Russotti (previously CTO) as Interim President and CEO; salary raised to $614,092.50.","Russotti received a one-time option grant of 318,750 shares at $3.16/share, vesting over 4 years.","Michael Diem, previously Chief Business Officer, promoted to CFO; compensation for new role TBD.","Board reduced from 8 to 7 members following Flores' departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323969,"accession_number":"0001104659-23-034217","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2023-03-20T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Century Therapeutics furnishes updated investor presentation; no specific new financial or pipeline details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing under Item 7.01 includes an investor presentation dated March 20, 2023, used in meetings with investors.","The presentation content is not fully disclosed; no earnings, pipeline, or corporate changes are specified.","No material new information can be extracted from the filing text or the limited exhibit excerpt provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323968,"accession_number":"0001104659-23-033066","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Century Therapeutics FY2022 net loss $130.9M; cash runway extended into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $130.9M for FY2022 vs $95.8M in FY2021; R&D expenses $97.2M (up 29%).","Cash, cash equivalents, and investments: $367.4M as of Dec 31, 2022; cash runway into 2026.","Collaboration revenue from BMS: $5.2M for FY2022.","Phase 1 ELiPSE-1 trial of CNTY-101 dosed first patient in Feb 2023; initial data by year-end 2023.","FY2023 GAAP operating expense guidance: $135M-$145M, incl. $12M-$17M stock-based comp."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323967,"accession_number":"0001104659-23-031507","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Century Therapeutics discloses ~$3M uninsured at SVB; less than 1% of total cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company has ~$3 million in cash/cash equivalents/restricted cash with SVB in excess of FDIC insurance limit.","Amount represents less than 1% of total cash, cash equivalents, restricted cash, and investments.","Company acknowledges SVB closure and FDIC appointment as receiver; monitoring situation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323966,"accession_number":"0001104659-23-002039","cik":1850119,"company_name":"Century Therapeutics, Inc.","ticker":"IPSC","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Century Therapeutics restructures pipeline, cuts headcount 25% to extend cash runway into 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["De-prioritizes CNTY-103 (glioblastoma) and discovery program; focuses on CNTY-101, CNTY-102, CNTY-107.","Reduces headcount by ~25%; closes labs in Seattle and Hamilton, consolidates research in Philadelphia.","Extends cash runway into 2026; Phase 1 CNTY-101 enrollment expected imminently; partnered BMS programs unaffected.","Hy Levitsky, President of R&D, resigns effective Jan 31, 2023; Luis Borges and Adrienne Farid assume responsibilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434655110.86767894,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-01-09T23:59:59+00:00|323966"}